Patents Examined by Shirley V. Gembeh
  • Patent number: 10377763
    Abstract: The purpose of the present invention is to provide a compound useful as a prophylactic or therapeutic agent for various diseases and symptoms related to orexin receptors, and a medical usage of the same. The present invention provides a morphinan derivative represented by the general formula (I) below or a pharmaceutically acceptable acid addition salt thereof, the morphinan derivative having excellent selectivity for and antagonism against orexin receptors and excellent therapeutic and prophylactic effects on drug dependence, and an orexin receptor antagonist and a therapeutic or prophylactic agent for drug dependence each containing it as an active ingredient.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: August 13, 2019
    Assignee: UNIVERSITY OF TSUKUBA
    Inventors: Hiroshi Nagase, Naoshi Yamamoto, Yoko Irukayama, Tsuyoshi Saitoh, Masashi Yanagisawa, Yasuyuki Nagumo
  • Patent number: 10369147
    Abstract: Compositions for topical administration of a hedgehog inhibitor compound are described. In one embodiment, the hedgehog inhibitor compound is patidegib and the topical composition comprises the compound in a solvent system of a monohydric primary alcohol and a polyol in a w/w ratio of between about 0.9-1.8. In another embodiment, the hedgehog inhibitor is itraconazole and the topical composition comprises the compound in a solvent system comprising a monohydric primary alcohol and an optionally lower alkyl end-capped oligomeric alkylene glycol in a w/w ratio of between about 0.8 and 2.6 and a fused bicyclic ether. Method of using the compositions are also described, where in one embodiment, the compositions are topically applied for treating or preventing basal cell carcinoma.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: August 6, 2019
    Assignee: PellePharm, Inc.
    Inventors: Marc Barry Brown, Cameron Robert Stevenson, Charles Rodney Greenaway Evans
  • Patent number: 10357505
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: July 23, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Somasekhar Bhamidipati, Rajinder Singh, Thomas Sun, Esteban Masuda
  • Patent number: 10357490
    Abstract: Disclosed are methods of treating neuroblastoma in a cancer patient by administration of a Trk inhibitor in combination with one more chemotherapeutic agents. Also disclosed are pharmaceutical compositions comprising a Trk inhibitor and one or more chemotherapeutic agents.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: July 23, 2019
    Assignee: IGNYTA, INC.
    Inventors: Zachary Dolph Hornby, Gang Li, David Wesley Anderson, Garrett M Brodeur, Radhika Iyer
  • Patent number: 10344014
    Abstract: An amorphous form of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile and a solid dispersion containing the amorphous form can be used extremely advantageously as drugs for oral administration.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: July 9, 2019
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Koji Shiraki, Tadanobu Nakayama, Tomoaki Ota
  • Patent number: 10342766
    Abstract: Derivatives of 6-shogaol are described herein. Also described herein are methods of preparing the derivatives, as well as methods of using the derivatives to activate Nrf2 and to treat diseases associated with inflammation and/or oxidative stress.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: July 9, 2019
    Assignees: North Carolina Agricultural and Technical State University, North Carolina Central University
    Inventors: Shengmin Sang, Yingdong Zhu, TinChung Leung
  • Patent number: 10342872
    Abstract: A method of inducing hair growth by topical administration of minoxidil is described, including topically applying minoxidil to a skin region susceptible to induction of hair growth, wherein the applied minoxidil is administered to the skin region (i) in a formulation comprising a release composition that mediates a dermal flux of minoxidil of at least 1.5 ?g minoxidil/cm2 skin area/hour for a time of from 17 to 27 hours, at an applied dose of from 2 to 20 mg minoxidil to said skin region, and with a period of from 16 to 30 hours before any subsequent reapplication of the formulation, or (ii) subsequent to administration to the skin region of said release composition so that the sequentially applied minoxidil and release composition together mediate the dermal flux of minoxidil of at least 1.
    Type: Grant
    Filed: February 25, 2018
    Date of Patent: July 9, 2019
    Assignee: CELMATRIX CORPORATION
    Inventor: Shane Malek
  • Patent number: 10342767
    Abstract: A pharmaceutically acceptable composition and method of therapy for a kinase-dependent malignancy in a patient in need of such therapy is provided. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for kinase-dependent malignancy. Also provided is a method to eradicate leukemia initiating cells (LIC) or cancer stem cells (CSC) in a patient being treated with a tyrosine kinase inhibitor.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: July 9, 2019
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Mohammad Azam, Meenu Kesarwani
  • Patent number: 10336966
    Abstract: The present invention relates to a composition having improved or enhanced fidelity and/or longevity of the fragrance profile, comprising fragrance materials in a diamond construction and at least one substantially non-odorous fragrance modulator. The invention also relates to methods of use of the compositions for perfuming suitable substrates, including hard surfaces and body parts, particularly skin and hair.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: July 2, 2019
    Assignee: The Procter & Gamble Company
    Inventors: Lynette Anne Makins Holland, Christelle Marie Sandrine Bonnet, Fabienne Pastor, Jose Maria Velazquez Mendoza, Jonathan Richard Stonehouse, William Eoghan Staite, David Thomas Stanton, Oreste Todini, Stephen Robert Schofield, Sarah Kyakyo Kanyunyuzi Nyakana, Susana Fernandez Prieto, Johan Smets, Jeffrey John Scheibel, Isabelle Guimet
  • Patent number: 10328065
    Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) alpha-isoform specific PI3K inhibitor and (b) a B-RAF inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 25, 2019
    Assignee: Novartis AG
    Inventors: Giordano Caponigro, Thomas Horn-Spirohn, Joseph Lehar
  • Patent number: 10328066
    Abstract: The present disclosure pertains to a pharmaceutical combination comprising (a) an alpha-isoform specific PI3K inhibitor, (b) a cyclin dependent kinase 4/6 (CDK4/6) inhibitor, and (c) an antimetabolite antineoplastic agent; combined preparations and pharmaceutical compositions thereof; the uses of such a combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 25, 2019
    Assignee: Novartis AG
    Inventors: Giordano Caponigro, Thomas Horn-Spirohn, Joseph Lehar
  • Patent number: 10322139
    Abstract: Formulations of comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a ?-cyclodextrin, e.g., a sulfo butyl ether ?-cyclodextrin, e.g., a ?-cyclodextrin, e.g., a sulfo butyl ether ?-cyclodextrin, e.g., CAPTISOL®; and methods of use in treating CNS disorders.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: June 18, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventor: Kiran Reddy
  • Patent number: 10322097
    Abstract: A quinonemethide triterpenoid is administered to subjects with multidrug-resistant cancer, in particular a cancer with enhanced expression and/or functional activity of ABC transporter proteins such as P-glycoprotein and/or an apoptosis-deficient, in particular p53-, Bax- or Bak-deficient, cancer, i.e. specific subgroups of subjects with cancer. The quinonemethide triterpenoid is suitable to treat cancer allowing for an accumulation of cytotoxic or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity towards the multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds. Methods for specifically targeting cancer cells with multidrug-resistance and methods for potentiating the activity of a chemotherapeutic compound in those cancer cells are also disclosed. A kit including a quinonemethide triterpenoid and a chemotherapeutic compound is also provided.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: June 18, 2019
    Assignee: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Kam Wai Wong, Yuen Kwan Law, Thomas Efferth, Su-Wei Xu, Sami Hamdoun, Liang Liu
  • Patent number: 10314814
    Abstract: A composition comprising 7-hydroxymatairesinol (HMR), or a stereoisomer, salt, complex, adduct or derivative thereof, or an extract containing them for preventing, alleviating or ameliorating the metabolic syndrome conditions.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: June 11, 2019
    Assignee: LINNEA S.A.
    Inventors: Marcello Luzzani, Massimiliano Carreri
  • Patent number: 10314799
    Abstract: The present invention provides use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus, for example, porcine epidemic diarrhea, porcine transmissible gastroenteritis, rotavirus diarrhea and the like.
    Type: Grant
    Filed: January 17, 2015
    Date of Patent: June 11, 2019
    Assignees: GENIFARM Laboratories Inc, GUANG ZHOU YUAN TU BIOLOGICAL AND CHEMICAL TECHNOLOGY CO. LTD
    Inventors: Yongdong Wang, Jiyuan Cao, Shifa Zhu, Wen Cheng, Zhipeng Huang
  • Patent number: 10314824
    Abstract: The present invention is directed to methods of treating, preventing, and/or ameliorating fibrosis syndrome, and in particular cardiac fibrosis, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: June 11, 2019
    Assignees: Cumberland Pharmaceuticals Inc., Vanderbilt University
    Inventors: Leo Pavliv, Bryan Voss, James West, Erica Carrier
  • Patent number: 10307486
    Abstract: The present disclosure relates to surface modified nanocrystalline cellulose (NCC) prepared by chemical modification of NCC as well as its use thereof, including as carrier of particular chemical compounds. The surface of nanocrystalline cellulose (NCC) was modified with chitosan oligosaccharide (CSOS) by selectively oxidizing the primary alcohol moieties of NCC followed by coupling of the amino groups of CSOS to the oxidized NCC to provide the desired material (NCC-CSOS).
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 4, 2019
    Assignee: Celluforce Inc.
    Inventors: Seyedeh Parinaz Akhlaghi, Kam Chiu Tam, Richard M. Berry
  • Patent number: 10300143
    Abstract: Described herein are compositions and methods relating to chemotherapeutic agent conjugates and the treatment of cancer.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: May 28, 2019
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Shiladitya Sengupta, Ashish Kulkarni, Poornima Rao, Bhaskar Roy
  • Patent number: 10300054
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: May 28, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Mark Todtenkopf
  • Patent number: 10300073
    Abstract: Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: May 28, 2019
    Assignee: The Regents of the University of California
    Inventors: Dominik Haudenschild, Jasper Yik